Kelly Gold
Chief Financial OfficerMs. Kelly Gold is Independent Director of X4 Pharmaceuticals, Inc. from July 1, 2026. Ms. Gold is the Chief Financial Officer at Camp4 Therapeutics Corporation from April, 2022 and was the Chief Business Officer and Senior Vice President of Finance at Camp4 Therapeutics Corporation since July 2021 and served as its Vice President of Corporate Development & Finance until July 2021. She was a Director at Camp4 Therapeutics Corporation. She is responsible for guiding and executing the company’s strategy for establishing innovative partnerships that allow CAMP4 to realize the full value of the Gene Circuitry Platform. Kelly also leads corporate finance and strategic financial planning activities at CAMP4. Prior to joining CAMP4, Kelly held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization. Prior to Biogen, Kelly worked in the healthcare investment banking group at Deutsche Bank, advising on M&A, public and private equity offerings, leveraged finance transactions and joint ventures to clients in the US, Latin America and Europe. She also worked in Deutsche Bank’s Latin American Investment Banking group in Mexico, executing dual-listed IPOs in the areas of financial services and oil and gas. Kelly began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 facilities operated by the CDC, the NIH and the US Army. Ms. Gold holds Bachelor’s degrees in Biochemistry, Life Sciences and Mechanical Engineering from Queen’s University in Ontario, as well as an MBA from the MIT Sloan School of Management.
Positions
- Company NameCamp4 Therapeutics CorporationStock CodeCAMPPositionChief Financial Officer
